Business
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, March 5 /CNW/ - Helix BioPharma Corp. (TSX: HBP /\nFrankfurt: WKN 918864)\n\n\nDr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a\ndeveloper of novel cancer therapeutics, will be presenting a scientific poster\nat the Fourth International Conference on Tumor Microenvironment, which runs\nfrom March 6th to 10th in Florence, Italy.\n\n\nThe conference, hosted by the International Cancer Microenvironment\nSociety, is a premier gathering of international cancer researchers who seek\nto develop cancer therapies targeting microenvironmental factors that control\ntumor growth and metastasis.\n\n\nThe poster, titled "L-DOS47 - a tumor microenvironment alkalization agent\nand a novel lung adenocarcinoma specific therapeutic candidate," provides a\nsummary of selected L-DOS47 previously announced findings. Included in the\nposter are laboratory data showing the ability of L-DOS47 to bind to and\ndestroy lung cancer cells alone and synergistically with selected\nchemotherapeutic drugs. Also being presented are mass tissue sample screening\ndata, which show that L-DOS47 binds not only to primary lung adenocarcinoma\ntissues preferentially over a host of other cancerous or normal tissues, but\nalso to metastasized cells in lymph nodes. The poster also highlights the\nability of L-DOS47 to localize and concentrate in tumor tissues specifically\nfollowing injection into laboratory animals\n\n\nA copy of the poster will be available on Helix's website for download at\nhttp://www.helixbiopharma.com.\n\n\nFor additional information on the Tumor Microenvironment conference,\nplease visit http://cancermicroenvironment.tau.ac.il/meeting-2007.html\n\n\nAbout L-DOS47\n\n\nL-DOS47 combines Helix's proprietary DOS47 new drug candidate with a\nhighly specific single domain antibody, to form a potential new targeted drug\nproduct for the treatment of adenocarcinoma of the lung, the most common form\nof cancer in the world today. L-DOS47 is thought to function by leveraging a\nnatural process in the body called the urea cycle, to produce an anti-cancer\neffect. It is based upon a naturally occurring enzyme called urease that\nessentially reverses the urea cycle by breaking down urea into metabolites\nthat include ammonia and hydroxyl ions. By doing so at the site of cancerous\ntissues in the body, L-DOS47 i...